NEWS

 

MBT™ Files Patent Applications in Key World Markets

Blyth, Ontario – February 20, 2013

 

Medicine for a Better Tomorrow (MBT) announces it has filed patent applications for Formulation V720, its revolutionary non-invasive influenza vaccine. Key world markets include the United States, 40 countries in Europe, China, Japan, Australia and Canada.

 

"This marks the beginning of the next stage of our journey," says Grant Sparling, CEO. "At the same time, MBT is considering additional studies and market research to more effectively engage companies interested in developing and commercializing V720™," he adds.

 

V720™ is an enteric capsule designed to pass through the digestive system, undisturbed until it reaches the small intestine. Medicine for a Better Tomorrow is represented by Borden Ladner Gervais (Toronto).

 

Medicine for a Better Tomorrow (MBT™) was founded by a team of high school students including, Grant Sparling, Rameez Virji, Lisa Tang, Krisha Patel, Somee Park, Vigne Sridharan, Jessica Zhu, Taha Al-Jishi, Rod Rodjanapiches, Vishal Babu and Sondus Bellow. The team of students worked on the project at a Shad Valley Enrichment Program hosted by Lakehead University in Thunder Bay, Ontario during the summer of 2010.

 

 

MBT™ Team Attending Universities Worldwide

Blyth, Ontario – August 28, 2012

 

Medicine for a Better Tomorrow (MBT™) was founded by a team of high school students including, Grant Sparling, Rameez Virji, Lisa Tang, Krisha Patel, Somee Park, Vigne Sridharan, Jessica Zhu, Taha Al-Jishi, Rod Rodjanapiches, Vishal Babu and Sondus Bellow. The team of students worked on the project at a Shad Valley Enrichment Program (http://www.shad.ca/) hosted by Lakehead University in Thunder Bay, Ontario during the summer of 2010.

 

The team co-invented a non-invasive influenza vaccination product known as Formulation V720™. It's an enteric capsule designed to pass through the digestive system, undisturbed until it reaches the small intestine.

 

Since then, MBT™ members have begun their university studies at leading schools worldwide. "This is a remarkable group of people and their ambition will ensure success in their courses of study – from economics and business to human biology and political science," says Grant Sparling. MBT™ President & CEO.

 

 

Global Patent Protection Initiative

Toronto, Ontario – August 15, 2012

 

MBT™'s ongoing V720™ patent protection initiative continues with consideration of global applications.

 

"This is a product that is remarkable for its simplicity. We are committed to seeing this through to its rightful conclusion – commercialization of V720™," says Grant Sparling, MBT™ President & CEO.

 

"MBT™ is represented by a very capable team from Borden Ladner Gervais [Toronto] and we are responsibly managing the process, and challenges as they are presented," Sparling adds.

 

Formulation V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile. Made with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system, undisturbed until it reaches the small intestine. This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies and invokes an immune response. Faster. Less expensive. No more needles.

 

 

Potential for Applications Beyond Influenza Vaccine

Blyth, Ontario – March 21, 2012

 

V720™ was designed as a non-invasive means of delivering an influenza vaccine – but the capsule is now being considered as a "delivery system" which may be suitable for use in other applications.

 

V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile. Made with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system, undisturbed until it reaches the small intestine. This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies and invokes an immune response. Faster. Less expensive. No more needles.

 

"We will continue to seek ways to protect the existing knowledge, and to broaden the potential application for this enteric capsule in response to other human health challenges, including response to large-scale weather and human-influenced disasters. This is very exciting to consider," says Grant Sparling. MBT™ President & CEO.

 

The enteric capsule was co-invented by a team of high school students including, Grant Sparling, Rameez Virji, Lisa Tang, Krisha Patel, Somee Park, Vigne Sridharan, Jessica Zhu, Taha Al-Jishi, Rod Rodjanapiches, Vishal Babu and Sondus Bellow. The team of students worked on the project at a Shad Valley Enrichment Program (http://www.shad.ca/) hosted by Lakehead University in Thunder Bay, Ontario during the summer of 2010.

 

 

Partners in This Process

Toronto, Ontario – November 16, 2011

 

"Members of the team are justifiably proud of the effort we are making in support of Formulation V720™. MBT™ is working to protect an idea and create its niche in a tough industry," says Grant Sparling, MBT™ President & CEO.

 

In Canada, an invention or discovery by a group or team is the intellectual property of the members of the group or team. The law makes no distinction within the group based on respective contributions, or claims of same, to the discovery.

 

"Each member of the team is equally credited with, and acknowledged in, all patent documents," adds Sparling. "We are partners in this process."

 

Known as Formulation V720™, the enteric capsule was co-invented by a team of high school students including, Grant Sparling, Rameez Virji, Lisa Tang, Krisha Patel, Somee Park, Vigne Sridharan, Jessica Zhu, Taha Al-Jishi, Rod Rodjanapiches, Vishal Babu and Sondus Bellow. The team of students worked on the project at a Shad Valley Enrichment Program (http://www.shad.ca/) hosted by Lakehead University in Thunder Bay, Ontario during the summer of 2010.

 

 

International Search Report

Toronto, Ontario – October 4, 2011

 

MBT™ continues the patent process for Formulation V720™, its revolutionary non-invasive influenza vaccine. It has received the International Search Report (ISR), and is proceeding with patent applications, world-wide.

 

"This is exciting for our team. The ISR provides us with the kind of encouraging information we need to continue. We are firm in our resolve," says Grant Sparling, MBT™ President & CEO.

 

Formulation V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile. Made with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system, undisturbed until it reaches the small intestine. This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies and invokes an immune response. Faster. Less expensive. No more needles.

 

 

MBT™ Files PCT Patent Application based on US Provisional Application

Toronto, Ontario – July 20, 2011

 

The advance of the world’s first non-invasive influenza vaccine continues with today’s PCT Patent Application based on a previously obtained US Provisional Patent.

 

Known as Formulation V720™, the capsule was co-invented by a team of high school students including, Grant Sparling, Rameez Virji, Lisa Tang, Krisha Patel, Somee Park, Vigne Sridharan, Jessica Zhu, Taha Al-Jishi, Rod Rodjanapiches, Vishal Babu and Sondus Bellow. The team of students worked on the project at a Shad Valley Enrichment Program (http://www.shad.ca/) hosted by Lakehead University in Thunder Bay, Ontario during the summer of 2010.

 

The students are conducting business as Medicine for a Better Tomorrow (MBT™), and in recent months, plans have developed to use the Formulation V720™ capsule as a delivery system to address a variety of global human health challenges, including those in developed and developing countries, areas of armed conflict, natural disaster and political unrest. MBT™ is represented by Borden Ladner Gervais, Toronto, Ontario.

 

Formulation V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile. Made with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system, undisturbed until it reaches the small intestine. This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies and invokes an immune response. Faster. Less expensive. No more needles.

 

 

MBT™ CEO Named one of "Canada's Top 20 Under 20" for 2011

Toronto, Ontario - June 2, 2011

 

MBT™ CEO Grant Sparling

Grant Sparling of Blyth, Ontario is recognized as one of "Canada’s Top 20 Under 20" by Youth in Motion at its 2011 Awards Breakfast held in Toronto.

 

"Youth in Motion recognizes and celebrates outstanding young leaders for their innovation, leadership and achievement," says Lisa Diamond, President and CEO. 

 

Grant is recognized for his second innovation – his first was a set of hybrid golf clubs when he was 13 years old - and perhaps the more remarkable, even revolutionary accomplishment, Formulation V720™.  "While attending the Shad Valley enrichment program for students, Grant and his team, Medicine for a Better Tomorrow, created Formulation V720™, the world’s first, and only, flu vaccine in pill form.  Eliminating mass immunization processes is not only cost effective, it reduces many problems associated with inoculations," says Ms. Diamond.

 

This fall, Grant will begin studies at Dartmouth College in Hanover, N.H., and is hoping to pursue a medical career.

 

Listen to Grant Sparling’s Radio Interview - CBC Ontario Morning

 

News Article - Shad Valley International

 

 

BioChemists Confirm Science Behind V720™

Blyth, Ontario - April 18, 2011

 

Ten credentialed Canadian scientists of various disciplines confirm the scientific theory behind Medicine for a Better Tomorrow's Formulation V-720.

 

"This validation is an exciting and integral development in the patent application process," says Grant Sparling, MBT™ CEO.  Although no details are being disclosed, Sparling confirms that laboratory testing will soon be underway in affiliation with a leading Canadian University - and that, "MBT™ will file a broadly worded patent by mid-July."

 

Formulation V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile.  Made with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system, undisturbed until it reaches the small intestine.  This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies and invokes an immune response.   Faster.  Less expensive.  No more needles.

 

 

V720™ Will Reduce Cost of Influenza Immunization

Blyth, Ontario – November 24, 2010

 

Hypodermic needles have been the primary delivery system for the influenza vaccine for over 60 years.  Recent studies confirm that the fear of needles is a top deterrent to higher vaccination rates.  Medicine for a Better Tomorrow introduces Formulation V720™.  A Better Way to Immunize – without needles.

 

"At Medicine for a Better Tomorrow, we have researched government mandates and we know that public health policy and immunization targets are developed based on a variety of factors", says Grant Sparling, MBT™ President & CEO.   With V720™, MBT™ can reduce the incidences of influenza, and help governments accomplish 3 specific goals

 

    1. Reduce healthcare costs;
    2. Reduce social and economic costs; and
    3. Reduce deaths due to influenza.

 

With Formulation V720™,  innovation, vaccine will delivered in the form of a uniquely designed capsule with an unmatched product benefit profile.  Most important, V720™ eliminates the fear of invasive and sometimes painful vaccination by hypodermic needles:

 

  • V720™ offers the potential for safe, cost-effective vaccination on an unprecedented scale to domestic markets.
  • V720™ will enable Canadian provincial and territorial governments to fulfill their vaccination mandates – while eliminating the burden on nurses, physicians, clinics and hospitals that currently administer the hypodermic vaccine.
  • V720™ will provide needle-averse patients of all ages with a simple self-administered capsule alternative.

 

MBT™ has addressed the significant underlying problem of producing a vaccine capsule which will remain structurally stable until it reaches the small intestine.  This ensures the influenza vaccine is activated only when it enters the small intestine and digestive fluids break apart the encasement of the capsule. This will release the vaccine into the lymphatic system. It is only then that the immune response is successfully initiated by the body, producing protection against the influenza virus.

 

The capsule is completely biodegradable and is fabricated from 100% organic, naturally derived ingredients.  Patents Pending.

 

 

MBT™ Advances Patent Application Process

Toronto, Ontario – November 10, 2010

 

Based on the results of a comprehensive patent review conducted by Borden, Ladner, Gervais LLP (Toronto) on behalf of Medicine for a Better Tomorrow, MBT™ confirms there are not any existing products with a similar design, components or product characteristics to Formulation V720™.  On the basis of this encouraging news, MBT™ announces it is proceeding with a formal patent application and will seek broadly-worded language to protect its design for a non-invasive vaccine delivery system.

 

"We are moving forward in the legal process, and while we must anticipate that there may be challenges to MBT™’s application, we are sufficiently prepared to support Formulation V720™ and look forward to whatever comes next", says MBT™ President & CEO, Grant Sparling.

 

Formulation V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile.  Made with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system, undisturbed until it reaches the small intestine.  This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies and invokes an immune response.   Faster.  Less expensive.  No more needles.

 

 

MBT™ Achievements Recognized at RIM Shad Cup

Waterloo, Ontario – November 5, 2010

 

Medicine for a Better  Tomorrow (MBT™) is recognized for its accomplishments in the development of Formulation V720™, MBT™’s non-invasive method for the delivery of influenza vaccine.  V720™ is the result of what began as a science and entrepreneurship competition including 50 teams of high school students working at 10 universities across Canada.  The top project from each campus advanced to the Research in Motion/Shad Cup national final held today in Waterloo, Ontario.

 

MBT™ advanced to the final with its solution to one of the greatest barriers to influenza vaccination:  the needle.  Unlike traditional hypodermic injection methods, V720™ is faster, less expensive, will enhance vaccination rates and reduce healthcare costs.

 

V720™ was recognized with First Place for "Best Application of Scientific Principles", First Place for "Best Marketing Plan", Third Place for “Best Business Plan” and was First Runner-Up in the National Championships.

 

 

"I am pleased for the MBT™ Team", says Grant Sparling, MBT™ President & CEO.  "This has been a remarkable amount of work, and so many people and their firms have enabled us and this project to gain momentum.  We look forward to the next stage in the patent process and the consideration of commercial strategies for Formulation V720™", adds Sparling.

 

 

New delivery method for influenza vaccine will
prevent deaths and reduce healthcare costs.

Toronto, Ontario – Sept. 5, 2010

 

Medicine for a Better Tomorrow announces a non-invasive vaccine delivery system, Formulation V720™ that, unlike traditional injection methods, will enhance vaccination participation rates and reduce healthcare costs.

 

Seasonal influenza results in about 1 billion worldwide cases of illness, 3 million to 5 million severe cases and about 250,000 to 500,000 deaths. In North America, over 40,000 Canadians and almost 400,000 Americans annually seek medical attention for seasonal influenza – and over 40,000 die. Of these 85% of deaths and 63% of hospitalizations attributable to influenza occur in persons 65 years of age and over.

 

2009 statistics in Ontario show that despite unprecedented efforts advising people to get their flu shot, only 42% of the population did so. Medicine for a Better Tomorrow’s President and CEO, Grant Sparling says "Our research indicated that as much as 34% of the population that does not currently receive an annual flu shot would want to be immunized if they could do so without an injection. We believe this product has the potential to not only prevent deaths but to substantially reduce healthcare costs."

 

Formulation V720™ is a uniquely designed capsule (Patent Pending) with an unmatched product benefit profile; with all natural components, the vaccine is contained within a capsule that has been designed to pass through the digestive system undisturbed until it reaches the small intestine. This ensures the vaccine is absorbed into the lymphatic system that aids in the production of antibodies, and invokes an immune response.

 

With no healthcare professional resources required for what could be a prescription, no hazardous bio-waste and an ability to administer anytime, anywhere, Formulation V720™ has the potential to revolutionize vaccination protocols worldwide.

 

RightLogo